ASCO 2025
Advertisement
Dr. Chakrabarti highlights 100% response with PD-1 blockade in dMMR rectal cancer and new chemoimmunotherapy for anal cancer.
Dr. Chakrabarti shares BREAKWATER, CheckMate 8HW, and CHALLENGE results improving metastatic colorectal cancer outcomes.
Dr. Chakrabarti highlights ATOMIC as the new standard for stage III dMMR colon cancer and compares it to the NICHE approach.
Dr. Lieu lists and describes DESTINY-Gastric04, CHALLENGE, MATTERHORN, BREAKWATER, and ATOMIC.
Dr. Weinberg recaps key ASCO Annual Meeting research, including MATTERHORN, ATOMIC CHALLENGE, BREAKWATER, and DYNAMIC-III.
Findings from the CheckMate 8HW trial highlight a potential shift in treatment strategy for patients with MSI-H/dMMR mCRC.
The use of neoadjuvant/perioperative gemcitabine with cisplatin can boost OS and R0 resection rates in patients with BTC.
Dr. He shares her insights on the evolving role of single-agent vs combination IO in the neoadjuvant setting for aHCC.
Dr. Janjigian shares why MATTERHORN was picked for the plenary and how its findings build on past studies in G/GEJ cancer.
Dr. Pietrantonio discusses how the benefits of T-DXd can potentially reshape the current treatment algorithm.
Dr. Weinberg explains why combining transcriptomic & genomic features can offer an advantage over prior biomarker ...
Dr. Picozzi details PANOVA-3, where TTFields with chemo showed significant survival gains in advanced pancreatic cancer.
Long-term results support the durable efficacy of binimetinib plus imatinib in treatment-naïve advanced GIST.
In the first-line HER2+ G/GEJ cancer, combinations of DV, toripalimab, and chemo produce high ORRs and promising early PFS.
Professor Tie discusses DYNAMIC-III, a trial using ctDNA to guide chemo escalation in stage III colon cancer.
Dr. Wainberg details the practice-changing implications of the MATTERHORN study event-free survival data.
Dr. Lieu highlights the randomized trial that looked at atezo with the standard of care for stage III dMMR colon cancer.
The findings are considered practice changing and support EC+mFOLFOX6 as a new SOC for BRAF V600E-mutant mCRC.
The ATOMIC trial showed that adding atezo to mFOLFOX6 significantly improves DFS in stage III colon cancer and dMMR.
Dr. Kelly discusses the first overall survival results from CheckMate 577 and how they compare to previous DFS results.
630 Madison Ave.
Manalapan, NJ 07726
About Column
Contribute Column
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.